Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRAP4S)

Drug Name

Acoramidis Drug Info

Synonyms

Acoramidis; AG-10; Acoramidis [USAN]; AG10; 1446711-81-4; T12B44A1OE; 3-[3-(3,5-Dimethyl-1h-Pyrazol-4-Yl)propoxy]-4-Fluorobenzoic Acid; UNII-T12B44A1OE; CHEMBL3940890; 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid; WHO 11205; Benzoic acid, 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluoro-; 4hiq; ACORAMIDIS [INN]; ACORAMIDIS [WHO-DD]; SCHEMBL15816954; BDBM50197885; AKOS040759821; HY-109165; CS-0116350; E79901; Q27451739; 16V

Indication

Disease Entry	ICD 11	Status	REF
Transthyretin amyloid cardiomyopathy	5D00.20	Phase 3	[1]

Cross-matching ID

PubChem CID: 71464713
TTD Drug ID: DMRAP4S

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Transthyretin (TTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Inotersen	DMJ93CT	Hereditary amyloidosis	5D00.2	Approved	[3]
ALN-TTRsc	DMFUOM7	Cardiomyopathy	BC43	Phase 3	[4]
NTLA-2001	DM1WDGE	Transthyretin amyloidosis	5D00	Phase 1	[5]
NI006	DM8U8KU	Amyloid transthyretin cardiomyopathy	5D00.20	Phase 1	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Transthyretin (TTR)	TTC1I86	TTHY_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03860935) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial). U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of AstraZeneca
3	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
4	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.
5	CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021 Aug 5;385(6):493-502.
6	Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N Engl J Med. 2023 Jul 20;389(3):239-250.